Valeant and Allergan's wining-and-dining shows pharma's faith in doctor influence

Payers may be grabbing the spotlight as script gatekeepers, but if the recently concluded takeover fight between Valeant ($VRX) and Allergan ($AGN) is any indication, doctors are still extremely influential--and companies still believe they can be influenced. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.